1. Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease 
Ali Ahmed, MD, Gregg C. Fonarow, MD, Yan Zhang, MS, MSPH, Paul W. Sanders, MD, Richard M. Allman, MD, Donna K. Arnett, PhD, Margaret A. Feller, MPH, Thomas E. Love, PhD, Inmaculada B. Aban, PhD, Raynald Levesque, MS, O. James Ekundayo, MD, DrPH, Louis J. Dell'Italia, MD, George L. Bakris, MD, Michael W. Rich, MD 
The American Journal of Medicine 
Volume 125, Issue 4, Pages (April 2012)
DOI: /j.amjmed
Copyright © Terms and Conditions

2. Figure 1
Absolute standardized differences comparing 56 baseline characteristics of older patients with systolic heart failure and chronic kidney disease receiving and not receiving discharge prescription of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, before and after propensity score matching.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © Terms and Conditions

3. Figure 2
Kaplan–Meier plots for all-cause mortality in a propensity-matched cohort of older patients with systolic heart failure with chronic kidney disease receiving and not receiving discharge prescription of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). CI=confidence interval.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © Terms and Conditions

4. Figure 3
Association of discharge prescription of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) with all-cause mortality in subgroups of propensity-matched older patients with systolic heart failure with chronic kidney disease. BP=blood pressure; CI=confidence interval; EF=ejection fraction; GFR=glomerular filtration rate.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © Terms and Conditions